Drug Profile
Research programme: photo induced nanoparticle-based therapeutics - PendreaBio
Alternative Names: KN 10; Photo immuno nano therapy - PendreaBio; Photo induced nanoparticle therapy programme - PendreaBio; Photo-immuno nanoparticle therapy - PendreaBio; PINTLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Keystone Nano
- Developer PendreaBio
- Class Antineoplastics; Calcium compounds; Immunotherapies; Phosphates
- Mechanism of Action Immunostimulants; Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Lung-cancer in USA (Parenteral)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Lung-cancer in USA (Parenteral)
- 26 Oct 2016 Photo induced nanoparticle-based therapeutics programme of Keystone Nano is available for licensing as of 26 Oct 2016. http://www.keystonenano.com/partnering/areas_of_interest